Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Experimental and Computational Approaches for SARS-CoV-2 Theranostics

Author(s): Ijaz Gul and Mohammad Amjad Kamal

Volume 28, Issue 46, 2022

Published on: 27 December, 2022

Page: [i - ii] Pages: 2

DOI: 10.2174/138161282846221227231152

« Previous
[1]
World Health Organization.. COVID-19 Weekly Epidemiological Update 2022.
[2]
Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe 2021; 29(4): 522-8.e2.
[4]
Chavda VP, Patel AB, Vora LK, et al. Nitric oxide and its derivatives containing nasal spray and inhalation therapy for the treatment of COVID-19. Curr Pharm Des 2022; 28: 3658-70.
[5]
Yadav D, Song M. Therapeutic applications of fucoidans and their potential to act against COVID-19. Curr Pharm Des 2022; 28: 3671-6.
[6]
Ansari MA, Alomary MN, Jamal QMS, et al. State-of-the-art Tools to Elucidate the therapeutic potential of TAT-peptide (TP) conjugated repurposing drug against SARS-CoV-2 spike glycoproteins. Curr Pharm Des 2022; 28: 3706-19.
[7]
Malla RR, Kamal MA. Tetraspanin-enriched microdomain containing CD151, CD9, and TSPAN 8 – Potential mediators of entry and exit mechanisms in respiratory viruses including SARS-CoV-2. Curr Pharm Des 2022; 28: 3649-57.
[8]
Pauly I, Singh AK, Kumar A, et al. Current insights and molecular docking studies of the drugs under clinical trial as RdRp inhibitors in COVID-19 treatment. Curr Pharm Des 2022; 28: 3677-705.

© 2024 Bentham Science Publishers | Privacy Policy